Inventor · disambiguated record
Manuel Allen Revez Ferreira
Also filed as: FERREIRA MANUEL · FERREIRA MANUEL A · FERREIRA MANUEL ALLEN REVEZ · FERREIRA MANUEL G
13 granted patents·31 pending applications·12 citations·filing 2004–2025
86Inventor score
Top patents by PatentIndex Score
44 records- 0192US11957704B2Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitorsREGENERON PHARMA·Filed 2022·Granted Apr 16, 2024·2 cites·11 claims
- 0292US11939635B2Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)REGENERON PHARMA·Filed 2021·Granted Mar 26, 2024·2 cites·20 claims
- 0391US11759476B2Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitorsREGENERON PHARMA·Filed 2022·Granted Sep 19, 2023·2 cites·16 claims
- 0487US11661731B2Splash out guardFERREIRA MANUEL A·Filed 2022·Granted May 30, 2023·3 cites·3 claims
- 0585US11359246B2Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitorsREGENERAN PHARMACEUTICALS INC·Filed 2021·Granted Jun 14, 2022·1 cites·29 claims
- 0684US11820982B2Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitorsREGENERON PHARMA·Filed 2021·Granted Nov 21, 2023·1 cites·7 claims
- 0784US11674177B2Kelch domain containing 7B (KLHDC7B) variants and uses thereofREGENERON PHARMA·Filed 2021·Granted Jun 13, 2023·1 cites·10 claims
- 0881US12258627B2Kelch domain containing 7B (KLHDC7B) variants and uses thereofREGENERON PHARMA·Filed 2023·Granted Mar 25, 2025·0 cites·19 claims
- 0981US2024252528A1Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1075US2024401136A1Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) Variants And Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1174US2024182973A1Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR)REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1274US2025170226A1Methods Of Treating Skin Cancer With Histidine Ammonia-Lyase (HAL) AgonistsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1373US2024102013A1Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) InhibitorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1472US2022184114A1Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) InhibitorsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1572US2025250631A1Kelch Domain Containing 7B (KLHDC7B) Variants And Uses ThereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1671US2024075102A1Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses ThereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1769US2025134920A1Treatment Of Myeloid Cell Dysfunction With Membrane Spanning 4-Domains A6A (MS4A6A) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1866US12186378B2Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonistsREGENERON PHARMA·Filed 2022·Granted Jan 7, 2025·0 cites·10 claims
- 1966US2022411870A1Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2065US12370257B2Materials and methods of treating MHC-I-opathy risk haplotypesREGENERON PHARMA·Filed 2022·Granted Jul 29, 2025·0 cites·13 claims
- 2165US11752197B2Macrophage stimulating 1 receptor (MST1R) variants and uses thereofREGENERON PHARMA·Filed 2020·Granted Sep 12, 2023·0 cites·23 claims
- 2265US2025084419A1Treatment Of Acne Rosacea With Pancreatic Lipase-Related Protein 3 (PNLIPRP3) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2363US12378557B2Treatment of sepsis with PCSK9 and LDLR modulatorsREGENERON PHARMA·Filed 2021·Granted Aug 5, 2025·0 cites·6 claims
- 2463US12049670B2Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereofREGENERON PHARMA·Filed 2021·Granted Jul 30, 2024·0 cites·7 claims
- 2563US2022064735A1Synaptojanin 2 (SYNJ2) Variants And Uses ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2662US2025375519A1Materials And Methods Of Treating MHC-1-Opathy Risk HaplotypesREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2761US2023193271A1Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2860US2023025878A1Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2960US2023041060A1Treatment of Varicose Veins With Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) AgonistsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3059US2023108957A1Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3159US2024084298A1Treatment Of Endometriosis With R-Spondin 3 (RSPO3) InhibitorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3257US2023074721A1Treatment Of Inflammatory Diseases With RAS Protein Activator Like 3 (RASAL3) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3357US2020370119A1Synaptojanin 2 (SYNJ2) Variants And Uses ThereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 3457US2023034093A1Treatment Of Cognitive Impairment With Alpha-N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5 (ST6GALNAC5) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3556US2023192864A1Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3656US2023107173A1Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function GenesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3756US2023023182A1Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3855US2023027007A1Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3954US2022307033A1Treatment Of Liver Disease With Ring Finger Protein 213 (RNF213) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 4053US2021300976A1Fascin-2 (FSCN2) Variants And Uses ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4151US2021371930A1Solute Carrier Family 26 Member 5 (SLC26A5) Variants And Uses ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4251US2022177982A1Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4347US2023059929A1Modulation Of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2)-Mediated Immune ResponseREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4445US2005268826A1Hexagonal table transformable to an alternate shapeFERREIRA MANUEL G·Filed 2004·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Manuel Allen Revez Ferreira files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →